SUO 2020 Program Book - suonet.org

Winter Scientific Program Co-Chairs:Peter E. Clark, MD & Edward M. Schaeffer, MD, PhD

#SUO20

PROGRAM BOOKSUO 21st Annual Scientific Meeting

Extraordinary Opportunities for DiscoveryDecember 3 – 5, 2020 | Virtual meeting

SUO/YUO Symposium on Clinical Research & Clinical TrialsDecember 2, 2020

Copyright © 2018 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.All rights reserved. ONCO-1246949-0000 02/18 keytruda.com

Visit keytruda.com/hcp to learn more about KEYTRUDA:

• Approved indications

• Resources for health care professionals

• The Merck Access Program

• KEY+YOU Support Program for patients

TABLE OF CONTENTS

1 Society of Urologic Oncology 21st Annual Scientific Meeting

Board of Directors ...............................................................................................................................3

Faculty Listing .....................................................................................................................................4

Promotional Partners ..........................................................................................................................6

Exhibitors & Contributors ...................................................................................................................7

General Information ............................................................................................................................8

CME Information ..................................................................................................................................8

Industry Satellite Symposium Events .............................................................................................10

General Scientific Program ..............................................................................................................11

Mark Your Calendars .........................................................................................................................20

Membership .......................................................................................................................................21

Virtual Platform ..................................................................................................................................22

AGENDA11:00 am–11:05 am Welcome and Introductions/Pre-test

11:05 am–11:50 am CASE-BASED CONVERSATIONS

1. New Paradigms in NMIBC: The Evolving Role of Checkpoint Inhibition2. Neoadjuvant Checkpoints: Exploring the Emerging Utility of ICI as a Neoadjuvant Modality3. Navigating Novelty in Advanced Disease: Current Evidence and Adaptive Strategies for Sequencing

ICI, FGFR Inhibitors, and Antibody-Drug Conjugates (ADC)

11:50 am–12:00 pm Post-test and Closing Remarks

CEC designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™.

Robert Dreicer, MD, MS, MACP, FASCOUniversity of Virginia School of Medicine

Charlottesville, Virginia

Neal D. Shore, MD, FACS Activity Chair

Atlantic Urology ClinicsMyrtle Beach, South Carolina

Ashish M. Kamat, MD, MBBS, FACSUniversity of Texas

MD Anderson Cancer CenterHouston, Texas

Supported by an independent educational grant from AstraZeneca.

Presented by Creative Educational Concepts, Inc. in collaboration with the Bladder Cancer Advocacy Network (BCAN).

Please join us for this LIVE VIRTUAL MEETING

Thursday, December 3, 2020 11:00 am–12:00 pm EST 2020

Register at https://tinyurl.com/SUO2020 or call 866-360-1717, ext.1100

What Clinicians Need to Know

EXAMINING THE USE OF NEWER AND EMERGING AGENTS IN BLADDER CANCER

Copyright © 2018 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.All rights reserved. ONCO-1246949-0000 02/18 keytruda.com

Visit keytruda.com/hcp to learn more about KEYTRUDA:

• Approved indications

• Resources for health care professionals

• The Merck Access Program

• KEY+YOU Support Program for patients

AN INNOVATIVE TECHNOLOGY. A FIRST-OF-ITS-KIND TREATMENT.See what sets JELMYTO apart at JELMYTO.com/hcp

JELMYTO is a trademark of UroGen Pharma, Ltd. © 2020 UroGen Pharma, Inc. All rights reserved. US-JEL-00291 10/20

S:8"S:10.625"

T:8.5"T:11"

B:9"B:11.375"

JEL033_BrandedReminder_JA_spc2_L1.indd 1 10/19/20 3:30 PM

BOARD OF DIRECTORS


AN INNOVATIVE TECHNOLOGY. A FIRST-OF-ITS-KIND TREATMENT.See what sets JELMYTO apart at JELMYTO.com/hcp

JELMYTO is a trademark of UroGen Pharma, Ltd. © 2020 UroGen Pharma, Inc. All rights reserved. US-JEL-00291 10/20

S:8"

S:10.625"

T:8.5"

T:11"

B:9"

B:11.375"

JEL033_BrandedReminder_JA_spc2_L1.indd 1 10/19/20 3:30 PM

OFFICERSPresidentMichael S. Cookson, MD, MMHC, FACS

President-ElectJeffrey M. Holzbeierlein, MD, FACS

SecretaryAdam S. Kibel, MD

TreasurerDaniel W. Lin, MD

Past PresidentChristopher P. Evans, MD, FACS

MEMBERS AT LARGEStephen A. Boorjian, MDBadrinath R. Konety, MD, MBABadar M. Mian, MD

STANDING COMMITTEE CHAIRSAwards Committee ChairChristopher P. Evans, MD, FACS

Bylaws Committee ChairRobert G. Uzzo, MD, MBA, FACS

Clinical Trials Committee ChairGennady Bratslavsky, MD

Education Committee ChairSeth P. Lerner, MD

Fellowship Committee ChairWade J. Sexton, MD

HistorianPaul H. Lange, MD

Journal Committee ChairMichael J. Droller, MD

Membership ChairSamir S. Taneja, MD

Nominating Committee ChairChristopher P. Evans, MD, FACS

OKAT RepresentativePeter E. Clark, MD

Rapid Response Committee ChairDavid F. Jarrard, MD

Young Urologic Oncologists RepresentativeBrian F. Chapin, MDSarah P. Psutka, MD, MS

SPRING SCIENTIFIC PROGRAM CO-CHAIRSBrian Cross, MDJohn L. Gore, MD, MS

WINTER SCIENTIFIC PROGRAM CO-CHAIRSPeter E. Clark, MDEdward M. Schaeffer, MD, PhD

PROGRAM COMMITTEE MEMBERS

Bladder CancerPeter C. Black, MD (Chair)Sam S. Chang, MD, MBA Siamak Daneshmand, MD Jen-Jane Liu, MD Joshua J. Meeks, MD, PhDElizabeth R. Plimack, MD, MSSima P. Porten, MD, MPHArlene O. Siefker-Radtke, MD

Health ServicesJohn L. Gore, MD, MS (Chair)Tracey L. Krupski, MD, MPHMark S. Litwin, MDBrian Rivers, PhD, MPHQuoc-Dien Trinh, MD

Kidney CancerE. Jason Abel, MD, FACS (Chair)Maria Carlo, MDSteven L. Chang, MD, MSJose A. Karam, MD Matthew I. Milowsky, MD Sarah P. Psutka, MD, MS Brian M. Shuch, MD

Testicular CancerTimothy A. Masterson, MD (Chair) Scott E. Eggener, MD Timothy Gilligan, MD Phillip M. Pierorazio, MD Joel Sheinfeld, MDAndrew J. Stephenson, MD

Prostate CancerIsla Garraway, MD, PhD (Chair)Christopher Barbieri, MD, PhDMichael S. Cookson, MD, MMHC, FACSMatthew R. Cooperberg, MD, MPHStacy Loeb, MD, MScAshley E. Ross, MD, PhDEdward M. Schaeffer, MD, PhDNima Sharifi, MDDaniel E. Spratt, MD

ORGANIZATIONAL REPRESENTATIVESABU LiaisonJ. Brantley Thrasher, MD, FACS

AJCC RepresentativeCheryl T. Lee, MD

AUA RepresentativeLeonard G. Gomella, MD, FACS

International LiaisonChristopher P. Evans, MD, FACS

LUGPA RepresentativeNeal D. Shore, MD, FACS

NCI LiaisonW. Marston Linehan, MD

WUOF LiaisonLaurence H. Klotz, MD

HEADQUARTER OFFICEWJ Weiser & Associates, Inc.1100 E. Woodfield Road, Suite 350Schaumburg, IL 60173P: (847) 264-5901 | F: (847) 517-7229

Executive DirectorBarbara Arango, MBA

FACULTY LISTING


E. Jason Abel, MD, FACSUniversity of Wisconsin School of MedicineMadison, WI

Nabil Adra, MDIndiana UniversityIndianapolis, IN

Peter Albers, MDDüsseldorf UniversityDüsseldorf, Germany

Gerald L. Andriole, Jr., MDWashington UniversitySt. Louis, MO

Aditya Bagrodia, MDUT Southwestern Medical CenterDallas, TX

Arjun Balar, MDNYU Langone HealthNew York, NY

Cris Bergerot, PhDCity of HopeDuarte, CA

Sumeet K. Bhanvadia, MDUniversity of Southern CaliforniaLos Angeles, CA

Peter C. Black, MDUniversity of British ColumbiaVancouver, BC

Gennady Bratslavsky, MDSUNY Upstate UrologySyracuse, NY

K. Clint Cary, MD, MPHIndiana University Medical CenterIndianapolis, IN

Brian F. Chapin, MDMD Anderson Cancer CenterHouston, TX

Toni Choueiri, MD, MSDana-Farber Cancer InstituteBoston, MA

Michael S. Cookson, MD, MMHC, FACSUniversity of OklahomaOklahoma City, OK

Matthew R. Cooperberg, MD, MPHUniversity of California, San FranciscoSan Francisco, CA

Siamak Daneshmand, MDUniversity of Southern California-Keck School of Medicine Los Angeles, CA

Scott E. Delacroix, Jr., MDLouisiana State University New OrleansNew Orleans, LA

Tanya B. Dorff, MDCity of HopeDuarte, CA

Tracy M. Downs, MD, FACSUniversity of Wisconsin School of MedicineMadison, WI

Scott E. Eggener, MDUniversity of Chicago Medical CenterChicago, IL

Thomas J. Fuchs, Dr. Sc.Memorial Sloan Kettering Cancer CenterNew York, NY

Matthew Galsky, MDMt. Sinai Medical CenterNew York, NY

Isla Garraway, MD, PhDUniversity of California, Los AngelesLos Angeles, CA

John L. Gore, MD, MSUniversity of Washington Medical CenterSeattle, WA

Abraham A. Hakimi, MDMemorial Sloan Kettering Cancer CenterNew Rochelle, NY

S. Duke Herrell, III, MD, FACSVanderbilt University Medical CenterNashville, TN

Jim Hu, MD, MPHWeill Cornell MedicineNew York, NY

Maha Hussain, MD, FACPNorthwestern UniversityChicago, IL

Randy Jones, PhD, RN, FAANUniversity of VirginiaCharlottesville, VA

Jose A. Karam, MDMD Anderson Cancer CenterHouston, TX

Max Kates, MDJohn Hopkins UniversityBaltimore, MD

Eric A. Klein, MDCleveland Clinic FoundationCleveland, OH

Vadim Koshkin, MDUniversity of CaliforniaSan Francisco, CA

Janet B. Kukreja, MD, MPHUniversity of Colorado DenverDenver, CO

Alexander Kutikov, MD, FACSFox Chase Cancer CenterPhiladelphia, PA

Cheryl T. Lee, MDOhio State UniversityColumbus, OH

Bradley C. Leibovich, MD, FACSMayo Clinic RochesterRochester, MN

Roger Li, MDH. Lee Moffitt Cancer CenterTampa, FL

W. Marston Linehan, MDUrologic Oncology Branch - National Cancer InstituteBethesda, MD

Jen-Jane Liu, MDOregon Health & Science UniversityPortland, OR

Brandon Mahal, MDUniversity of Miami Miller School of Medicine, Sylvester Comprehensive Cancer CenterMiami, FL

Jodi Maranchie, MD, FACSUniv of Pittsburgh Medical Center- ShadysidePittsburgh, PA

Viraj A. Master, MD, PhD, FACSEmory UniversityAtlanta, GA

Timothy A. Masterson, MDIndiana University Medical CenterIndianapolis, IN

FACULTY LISTING


Kara N. Maxwell, MD, PhDUniversity of PennsylvaniaPhiladelphia, PA

Joshua J. Meeks, MD, PhDNorthwestern University, Feinberg School of MedicineChicago, IL

Declan Murphy, MDPeter MacCallum Cancer CentreMelbourne, Australia

Katie S. Murray, DO, MS, FACSUniversity of MissouriColumbia, MO

Matthew J. Murray, MB, BChir, PhDUniversity of CambridgeCambridge, England

Neema Navai, MDMD Anderson Cancer CenterHouston, TX

Sumanta K. Pal, MDCity of Hope National Medical CenterDuarte, CA

Peter A. Pinto, MDNational Cancer InstituteBethesda, MD

Sima P. Porten, MD, MPHUniversity of California San FranciscoSan Francisco, CA

Sarah P. Psutka, MD, MSUniversity of WashingtonSeattle, WA

Ardeshir R. Rastinehad, DO, FACOSMount Sinai UrologyNew York, NY

Robert E. Reiter, MDUCLA Medical Center Los Angeles, CA

Chad R. Ritch, MD, MBAUniversity of Miami Leonard M. Miller School of MedicineMiami, FL

Brian Rivers, PhD, MPHMorehouse School of MedicineAtlanta, GA

Tracy Rose, MD, MPHUniversity of North CarolinaChapel Hill, NC

Ashley E. Ross, MD, PhDNorthwestern MedcineChicago, IL

John Sfakianos, MDMount Sinai- School of MedicineNew York, NY

Neal D. Shore, MD, FACSCarolina Urologic Research CenterMyrtle Beach, SC

Brian M. Shuch, MDUniversity of California, Los AngelesLos Angeles, CA

Minhaj Siddiqui, MDUniversity of MarylandBaltimore, MD

Arlene O. Siefker-Radtke, MDMD Anderson Cancer CenterHouston, TX

Arjun Sivaraman, MDWashington School of MedicineSt. Louis, MO

Eila C. Skinner, MDStanford UniversityStanford, CA

Angela B. Smith, MD, MSUniversity of North CarolinaChapel Hill, NC

Joseph A. Smith, Jr., MDVanderbilt University Medical CenterNashville, TN

Daniel E. Spratt, MDUniversity of Michigan Health SystemAnn Arbor, MI

Cora N. Sternberg, MDWeill Cornell MedicineNew York, NY

Kelly L. Stratton, MD, FACSUniversity of OklahomaOklahoma City, OK

Ian Thompson, Jr., MDSan Antonio, TX

Ulka N. Vaishampayan, MBBS, FABUniversity of MichiganAnn Arbor, MI

Shane Wells, MDUniversity of WisconsinMadison, WI

Christopher G. Wood, MD, FACSUniversity of Texas MD Anderson Cancer CenterHouston, TX

James S. Wysock, MD, MScNYU Langone HealthNew York, NY

PROMOTIONAL PARTNERS


Thank You to Our 2020 Promotional Partners(As of 11/18/2020)

Platinum Level Partner

Gold Level Partners

Silver Level Partners

CONTRIBUTORS & EXHIBITORS


Astellas Pharma and Pfizer Oncology

AstraZeneca

Bayer HealthCare

Blue Earth Diagnostics, Inc.

Bristol-Myers Squibb

CG Oncology, Inc.

EDAP TMS

Exact Sciences

FerGene

Ferring Pharmaceuticals, Inc.

Genentech

Invitae

Janssen Biotech, Inc.

Merck & Co., Inc.

Merck Pfizer Alliance

Myriad Genetics

Pacific Edge Diagnostics

Pfizer Oncology

Photocure

Progenics Pharmaceuticals, Inc.

TOLMAR Pharmaceuticals, Inc.

UroGen Pharma, Inc.

Thank You to Our 2020 Exhibitors(As of 11/18/2020)

Thank You to Our 2020 Contributors(As of 11/18/2020)

Creative Educational Concepts

Exelixis, Inc.

Gregor Diagnostics

PeerView

Prescient Health Care Group

GENERAL INFORMATION


2020 AWARD WINNERS

2020 Huggins Medal: Eila Skinner, MDThe Huggins Medal was established in 2001 in recognition of a major contribution and/or lifetime achievement in research and/or clinical practice that has contributed to the progress in the treatment for patients with genitourinary neoplasms. The SUO is proud to present the 2020 Huggins Medal to Dr. Eila Skinner, chair of the Department of Urology at Stanford University. Dr. Skinner received her undergraduate degree in human biology from Stanford and her medical degree from Keck USC Medical School. Her primary focus has been in the surgical treatment of locally advanced bladder cancer and is a nationally recognized expert in bladder reconstruction and continent urinary diversion.

2020 Richard D. Williams, MD Prostate Cancer Research Excellence Award:Eric Klein, MDSince 2013, the Urology Care Foundation has presented the Williams Award, named in honor of the late urologist, scientist, mentor, and humanitarian to an individual for outstanding and impactful research and work in the field of prostate cancer over the previous 10 years. The 2020 recipient, Dr. Eric Klein, was nominated by the SUO earlier this year. Dr. Klein is the Andrew C. Novick Distinguished Professor and chair of the Glickman Urological and Kidney Institute and the Lerner College of Medicine of Cleveland Clinic. Dr. Klein has made significant contributions to the management of early stage prostate cancer, with many publications related to surgical technique, outcomes, and clinical trials. In keeping with Dr. William’s legacy, Dr. Klein has mentored a generation of trainees and researchers at the Cleveland Clinic and beyond.

2020 Joseph A. Smith, Jr. Award:Joseph A. Smith, Jr., MDThe Joseph A. Smith, Jr. Award was established in 2020 as a tribute to Dr. Joseph Smith, who embodied the spirit of mentorship in the field of urologic oncology. As a fellow and trainee of the late Willet F. Whitmore, Dr. Smith learned first-hand the importance of strong mentorship in the development of a successful urologic surgeon. Of his numerous contributions that Dr. Smith made to urology, his proudest and most enduring was his role in mentoring careers of those in the field of urologic oncology. Dr. Smith will be the first recipient of this award.

EAU Lecturerer: Peter Albers, MDIn 2016, the SUO and the EAU Section of Oncologic Urology (ESOU) established a lectureship-exchange program in order to strengthen the relationship between the two Societies and to facilitate collaborations between European and American physicians. The SUO and the EAU independently selects a representative of their Society to present as a guest speaker at the other organization's Annual Meeting each year. This year, Dr. Albers will present on "PROBASE - The German Risk-Adapted PCA Screenign Trial - First Results.'

Dr. Albers is professor of urology and chairman of the Department of Urology, Heinrich-Heine-University Dusseldorf since 2008. In January 2018 he was elected medical director of the CIO Dusseldorf, Comprehensive Cancer Center at the University Hospital Dusseldorf. In January 2020 he was double appointed division head of the newly established division “Personalized Early Detection of Prostate Cancer” in the National Cancer Prevention Center of the German Cancer Research Center (DKFZ) in Heidelberg.

BOARD, COMMITTEE AND MEMBER MEETINGS

SUO Fellowship Committee MeetingDate: Wednesday, December 2, 2020Time: 6:00 p.m. - 7:00 p.m. Eastern

Young Urologic Oncologists (YUO) ProgramDate: Wednesday, December 2, 2020Time: 8:00 p.m. - 9:30 p.m. Eastern

SUO-CTC Board of Directors MeetingDate: Thursday, December 3, 2020Time: 10:00 a.m. - 12:00 p.m. Eastern

SUO Board of Directors MeetingDate: Thursday, December 3, 2020Time: 6:00 p.m. - 9:00 p.m. Eastern

SUO Fellowship Program Directors’ MeetingDate: Saturday, December 5, 2020Time: 10:00 a.m. - 11:00 a.m. Eastern

SUO Annual Business MeetingDate: Saturday, December 5, 2020Time: 2:30 p.m. - 3:00 p.m. Eastern

SUO Women in Urologic Oncology ProgramDate: Saturday, December 5, 2020Time: 5:00 p.m. - 6:30 p.m. Eastern

CME INFORMATION

Educational Needs and ObjectivesFor more information on the SUO Educational Needs and Objectives, please visit the SUO website at: suonet.org/meetings/upcoming-meetings/needs-objectives.aspx

CME Accreditation InformationFor more information on the SUO Accreditation details, please visit the SUO website at: suonet.org/meetings/upcoming-meetings/accreditation.aspx

The disclosure report for the SUO 21st Annual Meeting can be found online at: suonet.org/docs/meetings/disclosures.aspx

© Janssen Biotech, Inc. 2020 7/20 cp-75938v2

for an Educational Program

JOIN US

Presented byLawrence Karsh, MD

The Urology Center of ColoradoDenver, CO

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs. For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or government entity, that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

Please note that the company prohibits the off ering of gifts, gratuities, or meals to federal government employees/offi cials. Thank you for your cooperation.

This promotional educational activity is not accredited.

The program content is developed by Janssen Biotech, Inc. Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.

The personal information you provide may be used to contact you about your request to attend the Janssen Biotech, Inc., program. Information may be shared with Janssen Biotech, Inc., its affi liates, and a third party for the sole purpose of completing your registration for this program and as required by law.

Cliff Vestal, MDUrology Partners of North TexasFort Worth, TX

Thursday, December 3, 20201:00 PM – 2:00 PM EST SUO Virtual Annual MeetingVirtual Webinar

© Janssen Biotech, Inc. 2020 7/20 cp-75938v2

for an Educational Program

JOIN US

Presented byLawrence Karsh, MD

The Urology Center of ColoradoDenver, CO

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs. For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or government entity, that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

Please note that the company prohibits the off ering of gifts, gratuities, or meals to federal government employees/offi cials. Thank you for your cooperation.

This promotional educational activity is not accredited.

The program content is developed by Janssen Biotech, Inc. Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.

The personal information you provide may be used to contact you about your request to attend the Janssen Biotech, Inc., program. Information may be shared with Janssen Biotech, Inc., its affi liates, and a third party for the sole purpose of completing your registration for this program and as required by law.

Cliff Vestal, MDUrology Partners of North TexasFort Worth, TX

Thursday, December 3, 20201:00 PM – 2:00 PM EST SUO Virtual Annual MeetingVirtual Webinar

SYMPOSIUM EVENTS


THURSDAY, DECEMBER 3, 2020

1:00 p.m. - 2:00 p.m.

Industry Satellite SymposiumSponsored by: Janssen Biotech, Inc.

"Erleada: TITAN and New Data for SPARTAN Final Analysis”

Speakers: Cliff Vestal, MD Larry Karsh, MD

FRIDAY, DECEMBER 4, 2020

1:00 p.m. - 2:00 p.m.

Industry Satellite SymposiumSponsored by: Astellas Pharma and Pfizer Oncology

"Important Evidence-Based Changes in the Metastatic Castration-Sensitive Prostate Cancer Treatment Landscape”

Speaker: Neal Shore, MD, FACS

SATURDAY, DECEMBER 5 , 2020 10:00 a.m. - 11:00 a.m.

Industry Satellite SymposiumSponsored by: Merck & Co., Inc.

“A Treatment Approach for Certain Patients with High-Risk Non-Muscle Invasive Bladder Cancer*”*This program is not an accredited CME program.

Speaker: Gautam Jayram, MD

1:00 p.m. - 2:00 p.m.

Industry Satellite SymposiumSponsored by: AstraZeneca

“LYNPARZA® (olaparib): Results From A Key Clinical Trial”

Speaker: Neal Shore, MD, FACS


SUO/YUO SYMPOSIUMSpeakers and times are subject to change.

All sessions are listed in Eastern Time, US & Canada (UTC - 5:00)

Time Session

11:00 a.m. - 4:00 p.m. SUO/YUO Symposium on Clinical Reseaerch & Clinical Trials**Not CME Accredited

11:00 a.m. - 11:05 a.m. SUO President's WelcomePresident: Michael S. Cookson, MD, MMHC, FACS

11:05 a.m. - 11:15 a.m. SUO-CTC President's IntroductionPresident: Gennady Bratslavsky, MD

11:15 a.m. - 11:20 a.m. Program OverviewProgram Chair: Kelly L. Stratton, MD, FACS

11:20 a.m. - 12:00 p.m. Our Obligation to Clinical Trials: Urologists and SWOGSpeaker: Ian M. Thompson, Jr., MD

12:00 p.m. - 12:30 p.m. Developing Trials to Answer the Unanswered QuestionsSpeaker: Scott E. Eggener, MD

12:30 p.m. - 1:00 p.m. Increasing Enrollment of Underrepresented Populations in Clinical TrialsSpeaker: Tracy M. Downs, MD, FACS

1:00 p.m. - 2:00 p.m. Lunch/Networking Break

2:00 p.m. - 2:30 p.m. Finding Your Clinical Trial Sweet SpotSpeaker: Scott E. Delacroix, Jr., MD

2:30 p.m. - 3:00 p.m. Patient Centered Clinical Trial DevelopmentSpeaker: Angela B. Smith, MD, MS

3:00 p.m. - 4:00 p.m.

Panel: Surgical Trials: Best Trial by Disease State + Propose a Future Trial (Audience Vote)Moderator: Chad R. Ritch, MD, MBAPanelists: Sumeet K. Bhanvadia, MD Brian F. Chapin, MD Alexander Kutikov, MD, FACS

4:00 p.m. - 5:00 p.m. Virtual Networking Hour for Fellows and Trainees

WEDNESDAY, DECEMBER 02, 2020

In conjunction with the SUO Clinical Trials Consortium (SUO-CTC), the SUO has developed a half-day educational symposium on clinical research and clinical trials which will take place Wednesday, December 2, before the start of the SUO Annual Meeting program. This program seeks to ensure that each fellow has the tools required to quickly engage in clinical trials upon graduation and to facilitate

engagement in the SUO-CTC.

*A separate registration is required to attend this event. SUO fellows graduating 2020-2022 will receive complimentary registration.

SUO Clinical Trials Consortium (SUO-CTC)suoctc.org

The SUO-CTC overarching objective is to assist in the development of clinical trials in patients with urologic cancers and to participate in the conduct of network clinical trials involving therapeutic, diagnostic or prognostic procedures.

In support of our efforts the SUO-CTC offers national access to:

• Key patient populations• Physician thought leaders• Clinical-research expertise• Best practice methodology

GENERAL SCIENTIFIC PROGRAM


Time Session

11:00 a.m. - 12:00 p.m.

Expert Exchange 2020: Examining the Use of Newer and Emerging Agents in Bladder Cancer – What Clinicians Need to Know*Moderator: Neal Shore, MD, FACSSpeakers: Arjun V. Balar, MD Robert Dreicer, MD, MS Ashish M. Kamat, MD, MBBS *AMA PRA Category 1 Credits™ available

12:00 p.m. - 1:00 p.m.

Prostate Cancer Session I:Advances in Prostate Cancer DiagnosisSession Chair: Isla P. Garraway, MD, PhD

Targeted Versus Systematic Prostate Biopsy Speaker: Peter A. Pinto, MD

Transperineal Biopsy Update Speaker: Jim Hu, MD, MPH

Discussion/Q&A

Radiogenomics in Prostate Cancer Diagnosis Speaker: Robert E. Reiter, MD

Computer-Assisted Pathological Diagnosis Speaker: Thomas J. Fuchs, Dr. Sc.

The Role of PSMA Scanning in Prostate Cancer (Up)Staging Speaker: Declan Murphy, MD

Impact of PSMA Scans on Clinical Management - Point/Counterpoint Speakers: Matthew R. Cooperberg, MD, MPH Tanya B. Dorff, MD

Discussion/Q&A

Testicular Cancer SessionSession Chair: Timothy A. Masterson, MD

Panel Discussion on Biomarkers in Testis Cancer Speakers: Nabil Adra, MD Aditya Bagrodia, MD Matthew J. Murray, MB, BChir, PhD

Update on Role of Surgical Salvage/Late Relapse Surgery in Advanced GCT Speaker: Clint Cary, MD, MPH

Pro/Con: Minimally Invasive RPLND Speakers: Siamak Daneshmand, MD Scott E. Eggener, MD

Discussion/Q&A

1:00 p.m. - 2:00 p.m. Industry Sponsored Symposium

THURSDAY, DECEMBER 03, 2020

Speakers and times are subject to change.All sessions are listed in Eastern Time, US & Canada (UTC - 5:00)

WEDNESDAY, DECEMBER 02, 2020

Time Session

4:00 p.m. - 5:00 p.m. Virtual Networking Hour for Fellows and Trainees

8:00 p.m. - 9:30 p.m. Young Urologic Oncologists (YUO) Program

8:00 p.m. - 8:05 p.m. Welcome and IntroductionCommittee Chair: Sarah P. Psutka, MD, MS

8:05 p.m. - 8:11 p.m. Top Poster Presentations

8:11 p.m. - 8:19 p.m. Paper of the Year Award Presentation

8:19 p.m. - 8:24 p.m. Introduction to the Keynote LectureCommittee Chair: Brian F. Chapin, MD

8:24 p.m. - 9:10 p.m. Maintaining the Fire: Wellbeing, Resilience, and Intentional Culture Speaker: Taylor Riall, MD, PhD, FACS

9:10 p.m. - 9:30 p.m. Discussion/Q&A



Time Session

2:00 p.m. - 2:30 p.m. Joseph A. Smith, Jr. Mentorship LectureSpeaker: Joseph A. Smith, Jr., MD

2:30 p.m. - 3:00 p.m.

State-of-the-Art Lecture I: Past, Present, and Future of Surgical Robotics Meets Oncology: Strap in for the RideSpeaker: S. Duke Herrell, III, MD, FACS

Poster Presentations: Best of Prostate CancerModerator: Matthew R. Cooperberg, MD, MPH

#1 - RESETTING THE ACTIVE SURVEILLANCE CLOCK: APALUTAMIDE IN LOWER RISK PROSTATE CANCERPresenter: Michael Schweizer, MD

#2 - CAUSE OF DEATH DURING PROSTATE CANCER SURVIVORSHIP: A CONTEMPORARY US POPULATION-BASED ANALYSISPresenter: Adam B. Weiner, MD

#3 - APPLICATION OF DEEP LEARNING DETECTION AND GRADING SYSTEM FOR IDENTIFICATION OF CLINICALLY SIGNIFICANT PROSTATE CANCER ON WHOLE MOUNT PATHOLOGYPresenter: Nitin K. Yerram, MD

3:00 p.m. - 3:30 p.m. Exhibit Viewing and Networking

3:30 p.m. - 4:30 p.m.

Prostate Cancer Session IISession Chair: Isla P. Garraway, MD, PhD

Biomarker Review: Predictive/Actionable Biomarkers for Metastatic Prostate Cancer Speaker: Kara N. Maxwell, MD, PhD

Debate: Relugolix for Advanced Prostate Cancer is the New Standard (Hero Study)

Pro Speaker: Neal D. Shore, MD, FACS

Con Speaker: Ashley E. Ross, MD, PhD

Non-Metastatic CRPC – Prosper Trial Updates Speaker: Cora N. Sternberg, MD

New Second Line Therapy for mCRPC: PARPi: Results from PROfound Speaker: Maha Hussain, MD, FACP, FASCO

PARPi Counterpoint Speaker: Daniel E. Spratt, MD

Discussion/Q&A

Poster Presentations: Best of Testicular Cancer and Penile CancerModerator: Clint Cary, MD, MPH

#4 - SALVAGE RETROPERITONEAL LYMPH NODE DISSECTION IN THE SETTING OF RISING TUMOR MARKERS IN RELAPSED GERM CELL TUMORPresenter: Sean Q. Kern, MD

#5 - REAL-WORLD APPLICATION OF PRE-ORCHIECTOMY miR-371A-3P TEST IN TESTICULAR GERM CELL TUMOR MAN-AGEMENTPresenter: Rohit R. Badia

#6 - RACIAL AND SOCIOECONOMIC DIS-PARITIES IN ADJUVANT THERAPY AND SURVIVAL IN NONSEMINOMATOUS GERM CELL TUMOR: A POPULATION-BASED STUDYPresenter: Hriday Bhambhvani

#7 - ONCOLOGIC OUTCOMES OF MOHS SURGERY FOR LOCALIZED PENILE CAR-CINOMA: A 10-YEAR RETROSPECTIVE STUDYPresenter: Nicolas E. Alcalá

#8 - RISK FACTORS AND SURVIVAL OUT-COMES FOR UPSTAGING AFTER INGUI-NAL LYMPH NODE DISSECTION FOR cN1 PENILE SQUAMOUS CELL CARCINOMAPresenter: Nicholas Chakiryan, MD

#9 - PATTERNS OF RECURRENCE AFTER INGUINAL LYMPH NODE DISSECTION FOR PENILE SQUAMOUS CELL CARCINOMAPresenter: Nicholas Chakiryan, MD

4:30 p.m. - 5:30 p.m. Virtual Networking Hour

THURSDAY, DECEMBER 03, 2020 (CONT.)




Time Session

11:00 a.m. - 12:00 p.m.

Understanding the Evolving Treatment Landscape in Prostate Cancer: How to Leverage the Latest Advances and Strategies to Optimize Patient Outcomes”*This CME/MOC activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education. This educational activity is supported by independent medical educational grants from AstraZeneca, Clovis Oncology, Inc., Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Chair: William K. Oh, III, MDPresenter: Alicia K. Morgans, MD, MPH Evan Ya-Wen Yu, MD

12:00 p.m. - 12:30 p.m. Huggins Lecture: The (Short) History of Women in Urologic OncologySpeaker: Eila C. Skinner, MD

12:30 p.m. - 1:00 p.m.2020 EAU Lecture: PROBASE – The German Risk-Adapted PCA Screening Trial – First ResultsSpeaker: Peter Albers, MD


2:00 p.m. - 3:00 p.m.

Kidney Cancer Session ISession Chair: E. Jason Abel, MD, FACS

Economics of Kidney Cancer Speaker: John L. Gore, MD, MS

Evaluating the Psychosocial Impact of Kidney Cancer Treatments Speaker: Cris Bergerot, PhD

Can We Diagnose Renal Oncocytoma and Avoid Active Treatments? Speaker: Brian M. Shuch, MD

Emerging Biomarkers for Renal Cell Carcinoma Speaker: Abraham A. Hakimi, MD

Improving Selection of Patients for Cytoreductive Nephrectomy Speaker: Jose A. Karam, MD, FACS

Discussion/Q&A

Health Services Session: Health Disparities in Urologic CancersSession Chair: John L. Gore, MD, MS

Introduction Moderator: Cheryl T. Lee, MD

The Impact of Systemic Racism on Urologic Cancer Care Speaker: Brandon A. Mahal, MD

Stakeholder Engagement in Disparities Research in Urologic Cancers Speaker: Brian M. Rivers, PhD, MPH

Addressing Disparities Through Workforce Diversity, Equity, and Inclusion Initiatives Speaker: Randy A. Jones, PhD, RN, FAAN

Discussion/Q&A


FRIDAY, DECEMBER 04, 2020




Time Session

3:30 p.m. - 4:00 p.m.

SUO-CTC Session: Advances in Prostate Imaging and Focal Ablation of Prostate Cancer*Moderator: Gerald L. Andriole, Jr., MD*Not CME Accredited

Update on SUO-CTC Current TrialsSession Chair: Gerald L. Andriole, Jr., MD

Update on Imaging of Primary Prostate CancerSpeaker: James S. Wysock, MD, MSc

Use of Biomarkers to Select Patients for Active Surveillance and Focal AblationSpeaker: Minhaj Siddiqui, MD Critical Evaluation of Focal Ablation OutcomesSpeaker: Arjun Sivaraman, MD Clinical Trials of Focal AblationSpeaker: Ardeshir R. Rastinehad, DO, FACOS Panel Discussion and QuestionsModerator: Gerald L. Andriole, Jr., MDPanelists: Ardeshir R. Rastinehad, DO, FACOS Minhaj Siddiqui, MD Arjun Sivaraman, MD James S. Wysock, MD, MSc

Poster Presentations: Best of Kidney Cancer

#10 - ORAL HIF-2a INHIBITOR MK-6482 FOR VON HIPPEL-LINDAU (VHL) DISEASE–ASSOCIATED CLEAR CELL RENAL CELL CARCINOMA: EVALUATION OF RCC AND NON-RCC DISEASEPresenter: Ramaprasad Srinivasan, MD, PhD

#11 - PREVALENCE OF GERMLINE MUTATIONS IN CANCER SUSCEPTIBILITY GENES IN PATIENTS WITH EARLY ONSET RENAL CELL CARCINOMAPresenter: Hong Truong, MD, MS

#12 - THE ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT ON INSURANCE STATUS, CANCER STAGE, AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CANCERPresenter: Juan F. Javier-Desloges, MD

4:00 p.m. - 5:00 p.m.

Kidney Cancer Session IISession Chair: E. Jason Abel, MD, FACS

Classification of Renal Complex CystsSpeaker: Shane Wells, MD

Emerging Management of VHL ccRCCSpeaker: Jodi Maranchie, MD, FACS Modern Management of Bilateral RCCSpeaker: Bradley C. Leibovich, MD, FACS Integrating Surgery with Systemic Therapies for Metastatic RCCModerator: Sarah P. Psutka, MD, MSPanelists: Viraj A. Master, MD, PhD, FACS Sumanta K. Pal, MD Ulka N. Vaishampayan, MBBS, FAB Christopher G. Wood, MD, FACS

Discussion/Q&A

Poster Presentations: Best of Health Services and Other CategoryModerator: John L. Gore, MD, MS

#13 - THE EARLY IMPACT OF MEDICAID EXPANSION IN UROLOGIC MALIGNANCIES IN THE UNITED STATESPresenter: Xiaosong Meng, MD, PhD

#14 - THE IMPACT OF TELEMEDICINE ON PATIENT-REPORTED OUTCOMES IN UROLOGIC ONCOLOGYPresenter: Adam J. Gadzinski, MD, MS

#15 - ADVERSE EVENT PROFILE FOR COMBINATION CHEMOIMMUNOTHERAPY COMPARED TO CHEMOTHERAPY IN SOLID ORGAN MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALSPresenter: Mary E. Hall, MD

5:00 p.m. - 5:30 p.m. Breakout Discussion Groups

FRIDAY, DECEMBER 04, 2020 (CONT.)




Time Session

10:00 a.m. - 11:00 a.m. Industry Sponsored Symposium

11:00 a.m. - 12:00 p.m. Ask the Experts Breakout Sessions

12:00 p.m. - 1:00 p.m.

Bladder Cancer Session I: Non-Muscle Invasive & Upper Tract UCSession Chair: Peter C. Black, MD

Optimizing Management of High Risk NMIBC - Case-Based DiscussionModerator: Sima P. Porten, MD, MPHPanelists: Sumeet K. Bhanvadia, MD Janet B. Kukreja, MD, MPH Katie S. Murray, DO, MS, FACS Sarah P. Psutka, MD, MS

Molecular Characterization of NMIBC in the Clinical ContextSpeaker: John P. Sfakianos, MD

Next Generation Clinical Trial Design BCG-Unresponsive NMIBCSpeaker: Max Kates, MD

Debate: Neoadjuvant vs. Adjuvant Chemotherapy for UTUCModerator: Siamak Daneshmand, MD

NeoadjuvantSpeaker: Jen-Jane Liu, MD

AdjuvantSpeaker: Tracy L. Rose, MD, MPH

Discussion

Discussion Q&A


2:00 p.m. - 2:30 p.m.State-of-the-Art Lecture II: Advanced Kidney Cancer Update Speaker: Toni Choueiri, MD, MS

Poster Presentations: Best of Bladder CancerModerator: Roger Li, MD

#16 - DURABILITY OF RESPONSE TO CHEMOABLATIVE TREATMENT OF LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA WITH A MITOMYCIN-CONTAINING REVERSE THERMAL HYDROGEL: FINAL RESULTS OF THE OLYMPUS TRIALPresenter: Surena F. Matin, MD

#17 - GENOMIC CHARACTERIZATION OF RESIDUAL DISEASE AT RADICAL CYSTECTOMY FOLLOWING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCERPresenter: Andrew T. Lenis, MD, MS

#18 - FACTORS ASSOCIATED WITH DECISION REGRET IN PATIENTS UNDERGOING RADICAL CYSTECTOMY AND URINARY DIVERSIONPresenter: Elizabeth A. Green, MD

SATURDAY, DECEMBER 05, 2020




SATURDAY, DECEMBER 05, 2020 (CONT.)

Time Session

2:30 p.m. - 3:00 p.m. Annual Business Meeting & Awards

3:00 p.m. - 3:10 p.m. NIH UpdateSpeaker: W. Marston Linehan, MD


3:40 p.m. - 4:00 p.m. 2020 Richard D. Williams, MD Prostate Cancer Research Excellence AwardSpeaker: Eric A. Klein, MD

4:00 p.m. - 5:00 p.m.

Bladder Cancer Session II: Muscle Invasive & Metatstatic UC Session Chair: Peter C. Black, MD

Debate: Surgery Has a Role in Node-Only M1 UCModerator: Arlene O. Siefker-Radtke, MD

Pro SurgerySpeaker: Neema Navai, MD

Con SurgerySpeaker: Arjun Balar, MD

Discussion

Applying Lessons Learned from mUC to Perioperative Systemic Therapy of MIBCModerator: Joshua J. Meeks, MD, PhD

Systemic Therapy for mUCPanelist: Vadim S. Koshkin, MD

Peri-Operative Therapy for MIBCSpeaker: Kelly L. Stratton, MD, FACS

Roundtable DiscussionPanelists: Matthew D. Galsky, MD Vadim S. Koshkin, MD Kelly L. Stratton, MD, FACS

Discussion/Q&A

5:00 p.m. - 6:30 p.m.

Women in Urologic Oncology (WUO) Program

Courageous Leadership: From the Inside OutSpeaker: Natalie A. Johnson, MS

Policy: No Digital ReproductionCopyright of all materials on this website/webinar, including the text, illustrations, designs, audio clips, video clips, documents, products, and all other content is owned by SUO. No attendee/visitor may reproduce and distribute content through any recording, filming, screen shots/ photography, without advance approval of the SUO Executive Director.

This policy applies to all SUO members, non-members, guests and exhibitors, as well as members of the print, online or broadcast media.


July 2020.

Now Enrolling Patients with Non-Muscle Invasive Bladder Cancer

A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of sasanlimab (PF-06801591),† an anti-PD-1 antibody, in combination with Bacillus Calmette-Guerin (BCG) (Induction With or Without Maintenance) Versus BCG (Induction and Maintenance) in Participants with High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer

Now enrolling: United States, Europe, Asia

999participants

Combination of sasanlimab and alternative BCG Regimens to Evaluate outcomes with Subcutaneous anti-PD-1 Treatment

For more information about this trial please visit www.clinicaltrials.gov (NCT04165317) †Sasanlimab (PF-06801591) is an investigational medicinal product. This information is current as of July 2020.

CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer.

Our lead candidate, CG0070, is a selective oncolytic immunotherapy in multiple clinical programs, including ongoing trials with CG0070 as a monotherapy in a global Phase 3 study (BOND3) for the treatment of BCG-unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC), and also in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 study (CORE1) in the same indication. Additional indications in muscle-invasive bladder cancer (MIBC) and other solid tumors are being pursued with CG0070 in combination with immune checkpoint modulators. At CG Oncology, we aim to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide.

Phase 3 Study of CG0070 in Patients With Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)

BOND3 CLINICALTRIALS.GOV IDENTIFIER: NCT04452591

Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

CORE1 / KEYNOTE-935 CLINICALTRIALS.GOV IDENTIFIER: NCT04452591

Phase 1 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer (MIBC)

CORE2 CLINICALTRIALS.GOV IDENTIFIER: NCT04610671

CORPORATE PROFILE For more information, please contact [email protected] or visit www.cgoncology.com

Developing the next evolution of oncolytic immunotherapy for patients with advanced cancers.

CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer.

Our lead candidate, CG0070, is a selective oncolytic immunotherapy in multiple clinical programs, including ongoing trials with CG0070 as a monotherapy in a global Phase 3 study (BOND3) for the treatment of BCG-unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC), and also in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 study (CORE1) in the same indication. Additional indications in muscle-invasive bladder cancer (MIBC) and other solid tumors are being pursued with CG0070 in combination with immune checkpoint modulators. At CG Oncology, we aim to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide.

Phase 3 Study of CG0070 in Patients With Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)

BOND3 CLINICALTRIALS.GOV IDENTIFIER: NCT04452591

Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

CORE1 / KEYNOTE-935 CLINICALTRIALS.GOV IDENTIFIER: NCT04452591

Phase 1 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer (MIBC)

CORE2 CLINICALTRIALS.GOV IDENTIFIER: NCT04610671

CORPORATE PROFILE For more information, please contact [email protected] or visit www.cgoncology.com

Developing the next evolution of oncolytic immunotherapy for patients with advanced cancers.

MARK YOUR CALENDARS


ANNUAL MEETINGS

2021 SUO/SBUR Joint Meeting

September 11, 2021

Las Vegas, NV

2021 SUO Meeting at the AUA

September 11, 2021

Las Vegas, NV

2021 SUO MEETINGS AT THE AUA

22nd Annual Meeting of the SUO

December 1 - 3, 2021

Washington Marriott Wardman Park Hotel

Washington, DC

23rd Annual Meeting of the SUO

November 29 - December 2, 2022

Hilton San Diego Bayfront

San Diego, CA


SUO MEMBERSHIP

Discover more at LYNPARZAhcp.com

LYNPARZA is a registered trademark of the AstraZeneca group of companies. ©2020 AstraZeneca. All rights reserved. US-46441 Last Updated 10/20

HAVE YOU EXPLORED THE CLINICAL AND SAFETY DATA FOR CERTAIN USES?

Not an actual patient.

The Society of Urologic Oncology invites you to become an SUO member!

Member Benefits

• Communicate with other urologic oncologists and nonsurgical oncologists from multidisciplinary interaction

• Subscription to Urologic Oncology, the official journal of the Society of Urologic Oncology• Reduced meeting registration fees• Participate in NCI and cooperative group trials• Access to online members-only section

To apply for membership with the SUO, visit: suonet.org/membership

2020 VIRTUAL PLATFORM


SUO has partnered with Cadence to bring you the best virtual conference experience possible. Cadence is evolving the way people plan, experience, and remember events. Below are some of the features you can

expect to access during the SUO Scientific Meeting.

Live FeedCapture, share, and experience all of the

event's amazing moments.

ScheduleBuild a personalized schedule that fits your needs and

get alerts to ensure you don't miss a thing.

2020 VIRTUAL PLATFORM


PeopleRe-connect with colleagues and make new connections.

MessagingConnect via direct message and schedule one-on-one or group Zoom meetings quickly and esaily

When it comes to prostate cancer imaging, accurate detection lies in the details.1 And you can’t treat what you can’t detect. Using optimal technology, targets, tracers, and tools such as PET, PSMA, 18F, and AI systems could improve diagnostic performance and help pave the way for more informed prostate cancer treatment decisions.1-5

We are investigating ways to take imaging to the next level. Learn how at FoursightProstateCancer.com

References: 1. Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Oncol. 2019;11:1-14. doi.org/10.1177/1758835919876828 2. Petersen L, Zacho HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer; an expedited systematic review. Cancer Imaging. 2020;1-8. doi:10.1186/s40644-202-0290-9 3. Tan N, Oyoyo U, Bavadian N, et al. PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. Radiology. 2020;296:44-55. doi.org/ 10.1148/radiol.2020191689 4. Zippel C, Ronski SC, Bohnet-Joschko S, Giesel FL, Kopka K. Current status of PSMA-radiotracers for prostate cancer: data analysis of prospective trials listed on clinicaltrails.gov. Pharmaceuticals. 2020;1-13. doi:10.3390/ph13010012 5. Data on file. Progenics Pharmaceuticals, Inc.

Trademarks, registered or otherwise, are the property of their respective owners. © 2020 Lantheus Holdings, Inc. All rights reserved. PM-US-PY-0033

CREATING A NEW VISION FOR PROSTATE CANCER IMAGING

F O U R S I G H T

40 mg tablets 80 mg tablets

XTANDI will be offered in a new tablet formulation*

Visit XtandiTablets.com to learn moreNot actual size of tablets.

*Beginning March 2021, please specify “XTANDI 40 mg tablets” or “XTANDI 80 mg tablets” when prescribing XTANDI to your patients.

© 2020 Astellas Pharma US, Inc. and Pfi zer Inc. All rights reserved. 076-6119-PM 11/20XTANDI, Astellas, and the fl ying star logo are registered trademarks of Astellas Pharma Inc.

AVAILABLE SOON

40 mg 80 mg

1666869-PFAXTI_SUO Half-Page Ad Rv2.indd 11666869-PFAXTI_SUO Half-Page Ad Rv2.indd 1 10/29/20 11:48 AM10/29/20 11:48 AM

NOW covered by MEDICAREThe Non-Invasive Genomic Urine Test Optimized for the Detection and Management of Bladder Cancer

In-Home Sampling Now Available

Discover more at www.Cxbladder.com or call 1-855-292-5237

PE-CxBladder Medicare Journal Ad 8.5x5.5 V1.indd 1PE-CxBladder Medicare Journal Ad 8.5x5.5 V1.indd 1 10/2/20 3:37 PM10/2/20 3:37 PM

Two Woodfield Lake1100 E. Woodfield Road, Suite 350

Schaumburg, IL 60173

P: (847) 264-5901 | F: (847) 517-7229Email: [email protected]: suonet.org

The SUO is on Facebook & Twitter – Connect with us Today!

@UroOnc

SUO Clinical Trials ConsortiumP: (847) 264-5901 | F: (847) 517-7229

Email: [email protected]: suoctc.org

Date post:	26-Oct-2021
Category:	Documents
Upload:	others
View:	8 times
Download:	0 times

SUO 2020 Program Book - suonet.org

Documents